Besides the front-line maintenance therapy, is any positive impact of poly (ADP-ribose) polymerase (PARP) inhibitors on recurrent high-grade ovarian cancer?
Yiu-Tai Li, Peng‐Hui Wang
Topics & Concepts
Poly ADP ribose polymeraseFront lineOvarian cancerPolymerasePARP inhibitorCancer researchMaintenance therapyMedicineOncologyCancerInternal medicineBiologyEnzymeBiochemistryChemotherapyPolitical scienceLawOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyToxin Mechanisms and Immunotoxins